Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2022-10-26 Governance Information
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
对外担保管理制度
Governance Information Classification · 95% confidence The document is titled "北京三元基因药业股份有限公司 对外担保管理制度" which translates to "Beijing Sanyuan Gene Pharmaceutical Co., Ltd. External Guarantee Management System." It details the company's internal policy and procedures regarding external guarantees, including approval processes, risk control, information disclosure, and responsibilities. The document includes references to board and shareholder meetings approving the policy but does not contain financial statements, earnings data, or audit results. It is a governance-related document outlining internal rules and procedures rather than a financial report or announcement. The document length is 4601 characters, which is substantial and contains the full policy text, not just an announcement. Therefore, the most appropriate classification is Governance Information (CGR).
2022-10-26 Chinese
监事会制度
Governance Information Classification · 95% confidence The document is titled as the Supervisory Board System of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the rules, procedures, and responsibilities of the Supervisory Board, including meeting protocols, voting procedures, and supervisory powers. It references relevant laws and company articles but does not contain financial statements, audit opinions, or financial results. It is a governance-related document outlining internal rules and structure of the supervisory board. The document length is 3942 characters, which is relatively short but contains substantive governance content rather than just an announcement. Therefore, it fits best under Governance Information (CGR).
2022-10-26 Chinese
征集投票权实施细则
Governance Information Classification · 95% confidence The document is titled as "征集投票权实施细则" which translates to "Implementation Rules for Soliciting Voting Rights." It is a detailed procedural document issued by the company's board regarding the solicitation of voting rights for shareholders in the context of a shareholders' meeting. The content includes legal references, procedural rules, responsibilities of solicitors, and formats for voting authorization. There is no financial data, no audit information, no earnings or annual report content, nor is it a simple announcement or certification. It is a governance-related document detailing internal rules and procedures related to shareholder voting rights solicitation. Therefore, it fits best under Governance Information (CGR). The document length is 3216 characters, which is substantive and not a brief announcement. Hence, the classification is CGR with high confidence.
2022-10-26 Chinese
关于对拟认定核心员工进行公示并征求意见的公告
Board/Management Information Classification · 95% confidence The document is a public announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the nomination and public disclosure of proposed core employees. It includes a list of nominated core employees, a public comment period, and mentions that the nomination requires further approval by the supervisory board and shareholders' meeting. There is no financial data, no mention of financial results, no regulatory certifications, or report attachments. The document is an announcement related to internal company personnel matters, specifically about core employee nominations, which aligns with management or board-related information. It is not a full report, audit, or financial release. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short and focused on personnel nomination, not a report publication or regulatory filing.
2022-10-26 Chinese
总经理工作制度
Governance Information Classification · 95% confidence The document is a detailed description of the General Manager's work system of Beijing Sanyuan Gene Pharmaceutical Co., Ltd., including the responsibilities, authority, meeting procedures, and reporting system of the General Manager. It is approved by the company's board of directors and includes governance-related content such as company law references, board resolutions, and internal management rules. There is no financial data, no audit information, no earnings or capital updates, and no shareholder voting results. The document focuses on internal governance structure and management rules, which fits the definition of Governance Information (CGR). The document length is 2254 characters, which is relatively short but contains substantive governance content rather than just an announcement or summary. Therefore, the appropriate classification is Governance Information (CGR).
2022-10-26 Chinese
对外投资管理制度
Governance Information Classification · 95% confidence The document is titled '北京三元基因药业股份有限公司 对外投资管理制度' which translates to 'Beijing Sanyuan Gene Pharmaceutical Co., Ltd. External Investment Management System'. It is a detailed internal policy document outlining the company's procedures and rules for external investments and financing, including approval authorities, organizational responsibilities, execution controls, financial management, auditing, and disclosure obligations. The document includes references to company law, securities exchange rules, and internal governance but does not contain financial statements, earnings data, or audit results. It is not a report of financial results, audit, or earnings release, nor is it a brief announcement or presentation. It is a governance-related document detailing internal rules and procedures for investment and financing management. Therefore, the most appropriate classification is Governance Information (CGR). The document length (6286 characters) supports it being a full policy document rather than a short announcement or notice.
2022-10-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.